

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



ADICON Holdings Limited

艾迪康控股有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9860)

VOLUNTARY ANNOUNCEMENT FINANCIAL AND BUSINESS UPDATE

This announcement is made by the board (the “**Board**”) of directors (the “**Directors**”) of ADICON Holdings Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders of the Company and potential investors about the latest business update of the Group for the third quarter of 2023.

Based on preliminary review of the unaudited consolidated management accounts of the Group for the three months ended September 30, 2023 and the information currently available to the Board, the Group’s revenue for the three months ended September 30, 2023 is estimated to be approximately RMB795 million in comparison to three months ended September 30, 2022 of approximately RMB1,171 million.

In the third quarter of 2023, the Group broadened its testing service offering by launching two new independent clinical laboratories (the “**ICLs**”) in Shijiazhuang and Ouhai, Wenzhou as well as the completion of the laboratory relocation and expansion in Chengdu. Our Shijiazhuang laboratory received recognition of being in the Shijiazhuang High-tech Zone and is an important component in furthering its penetration in the northern region. Ouhai laboratory is a regional inspection center working alongside the local government. The expanded Chengdu laboratory will significantly expand the Group’s production capacity and be a technology center for its western region.

The Group is committed to continuously serving the patients and the general public with its high-quality testing services as a leading ICL service provider in China, and becoming a trusted and reliable partner for medical professionals and the general public.

The information contained in this announcement is based on a preliminary review of the unaudited consolidated management accounts of the Group and the information currently available to the Board, and is not based on any figure or information which has been audited or reviewed by the independent auditors of the Company or the audit committee of the Board. The information contained in this announcement may be subject to change or adjustment. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
ADICON Holdings Limited
Ms. YANG Ling
Chairwoman

Hong Kong, October 29, 2023

As of the date of this announcement, the Board comprises Mr. GAO Song as executive Director; Ms. YANG Ling, Mr. LIN Jixun, Ms. FENG Janine Junyuan and Ms. LIM Kooi June as non-executive Directors; and Mr. MI Brian Zihou, Mr. YEH Richard and Mr. ZHANG Wei as independent non-executive Directors.